CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
12th Annual World ADC London 2022 – Presentations
World ADC 2022 presentation titled, “A New Molecular Class to target Tumor Immunity by both disrupting the tumor and enabling the immune system” presented by Trevor Hallam, Ph.D., President of Scientific and Chief Scientific Officer.World ADC 2022 presentation...
Cowen 42nd Annual Healthcare Conference – Presentation
Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
63rd American Society of Hematology (ASH) Annual Meeting and Exposition – Non-Audio Presentation
40th Annual J.P. Morgan Heathcare Conference – Presentation
Webcast, Jan 13, 2022 at 11:15AM EST
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation
Webcast, Jan 5, 2022 at 5:00pm EST
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. - Tumor proportion score...
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
- Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1 dose-expansion cohort at Company event scheduled for Wednesday, Jan. 5, 2022 at 5 pm ET, or 2 pm PT SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 – Sutro Biopharma, Inc. (“Sutro”),...
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
– Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development...
